Recent studies into retatrutide, a dual activator for GLP-1 and GIP receptors, are revealing significant results in addressing excess mass and diabetes 2 condition. Initial data suggest a distinct mechanism https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/